Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Pliant Therapeutics' stock plummeted, but Kevin Tang’s stake raises takeover hopes. Find out why PLRX stock’s cash reserves ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...

Pliant Therapeutics, Inc.’s PLRX share price has dipped by 10.89%, which has investors questioning if this is right time to ...

The best softside luggage is flexible and forgiving, often providing extra packing space. After rigorous testing, our editors ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two ...

Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options ...

Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

If Trump continues to defy judges, and Congress remains pliant, then our constitutional form of government is essentially meaningless. It is not a stretch to wonder if the American dictatorship Trump ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biopharmaceutical company currently valued at $94.3 million, announced interim results from a Phase 1 clinical trial of PLN-101095 ...